Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126,468,243
-
Total 13F shares
-
76,219,647
-
Share change
-
-5,430,574
-
Total reported value
-
$102,134,785
-
Put/Call ratio
-
29%
-
Price per share
-
$1.34
-
Number of holders
-
117
-
Value change
-
-$10,719,386
-
Number of buys
-
55
-
Number of sells
-
62
Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q3 2023
As of 30 Sep 2023,
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) was held by
117 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
76,219,647 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, Avidity Partners Management LP, Palo Alto Investors LP, CITADEL ADVISORS LLC, JACOBS LEVY EQUITY MANAGEMENT, INC, GEODE CAPITAL MANAGEMENT, LLC, MARSHALL WACE, LLP, STATE STREET CORP, and GOLDMAN SACHS GROUP INC.
This page lists
117
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.